A potential role of ruxolitinib in leukemia

. Author manuscript; available in PMC: 2014 Aug 26.

Published in final edited form as: Expert Opin Investig Drugs. 2011 Jun 3;20(8):1159–1166. doi: 10.1517/13543784.2011.589383

Drug name (generic)	Ruxolitinib (INCB018424)
Phase	Currently in Phase III
Indication	Treatment of relapsed/refractory leukemia
Pharmacology description/mechanism of action	Selective inhibitor of JAK1 and JAK2
Route of administration	Oral
Chemical structure	C₁₇H₂₁N₆O₄P*

Pivotal trial(s)	Patients with either primary or post-ET and post-PV myelofibrosis (NCT:00952289)
	Patients with polycythemia that are hydroxyurea resistant, refractory, or intolerant (NCT:01243944)

ET: Essential thrombocythemia; PV: Polycythemia vera.